SCHEMBL3247541

SCHEMBL3247541

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(N(C)S(=O)(=O)c4ccccc4)cc3c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
RECQL P46063 2/20 0.44
MAPT P10636 2/20 0.44
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
GABRB1 P18505 1/20 0.41
GABRA3 P34903 1/20 0.41
KDM4E B2RXH2 3/20 0.41
TP53 P04637 2/20 0.40
CLEC4M Q9H2X3 2/20 0.40
THRB P10828 1/20 0.40
ADRB2 P07550 1/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3254539 0.91 MAPT (0.48) MEN1KMT2ARECQLMAPTCRHBP
SCHEMBL3252448 0.88 GABRA1 (0.42) MEN1KMT2ARECQLMAPTGABRA1
SCHEMBL3242740 0.88 HPGD (0.48) MEN1KMT2ARECQLKDM4ECLEC4M
SCHEMBL3246214 0.86 HSD17B10 (0.55) MEN1KMT2ARECQLMAPTCRHBP
SCHEMBL3250657 0.85 CRHBP (0.49) MEN1KMT2ARECQLMAPTCRHBP
SCHEMBL3251817 0.85 CRHBP (0.49) MEN1KMT2ARECQLMAPTCRHBP
SCHEMBL3251608 0.85 JAK2 (0.47) MEN1KMT2AMAPTGABRA1GABRB2
SCHEMBL3249025 0.83 MAPT (0.52) MEN1KMT2ARECQLMAPTCRHBP
SCHEMBL3255494 0.82 MAPT (0.44) MEN1KMT2ARECQLMAPTCRHBP
SCHEMBL3254915 0.82 MAPT (0.47) MEN1KMT2ARECQLMAPTGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MEN1 3749/4885KMT2A 1882/4885RECQL 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.